# T-kininogen induces endothelial cell proliferation

Viviana Pérez<sup>a</sup>, Elías Leiva-Salcedo<sup>a</sup>, Claudio Acuña-Castillo<sup>a</sup>, Mauricio Aravena<sup>a</sup>, Christian Gómez<sup>a</sup>, Valeria Sabaj<sup>a</sup>, Alicia Colombo<sup>a</sup>, Sumiyo Nishimura<sup>a</sup>, Claudio Pérez<sup>a</sup>, Robin Walter<sup>a,b</sup>, Felipe Sierra<sup>a,b,\*</sup>

<sup>a</sup> Instituto de Ciencias Biomédicas, Programa de Biología Celular y Molecular and Centro FONDAP de Estudios Moleculares de la Célula, Facultad de Medicina, Universidad de Chile, Independencia 1027, Santiago, Chile

<sup>b</sup> Lankenau Institute for Medical Research, 100 Lancaster Ave., Wynnewood, PA 19096, USA

#### Abstract

Basal proliferation of endothelial cells increases with age, and this might play a role in the etiology of age-related vascular diseases, as well as angiogenesis. Serum kininogen levels increase during aging in rats and humans, and T-kininogen (T-KG) can affect proliferative homeostasis in several cell models. Both kinins and kininogens have been shown previously to be angiogenic through activation of endothelial cell proliferation, and here we show that exposure of endothelial cells to T-KG results in vigorous cell proliferation, accompanied by ERK/AKT activation. In our experiments, the proliferative response requires B1 and B2 kinin receptors, even though kinins are not released from the precursor. We hypothesize that the age-related increase in T-KG could play a significant role in the age-related dysregulation of vascular physiology and function.

Keywords: Endothelial cells; T-KG; Kinin receptors; ERK; Cell proliferation; Aging

# 1. Introduction

Aging is a complex process characterized by a general decline in physiological functions, including significant changes in proliferative homeostasis. While proliferative arrest is the most prominent landmark of a commonly used cellular model of aging, fibroblasts in culture (Cristofalo et al., 1998), not all cell types exhibit a decreased proliferative capacity with age (Holt and Yeh, 1988; Prakash et al., 2002). In some tissues, including the prostate and the vascular endothelium, aging is often accompanied by pathology that includes increased proliferation. Due to its role in haemostatic control and angiogenesis, the vascular endothelium represents a particularly vulnerable tissue (Yu and Chung, 2001; Yeh et al., 2000; Cines et al., 1998).

Impairment of endothelial cell function is believed to contribute significantly to the increased severity of cardiovascular diseases in the geriatric population. In the young adult, endothelial cells are remarkably quiescent (Cines et al., 1998), but they can be easily induced into active proliferation, for example as a result of traumatic injury or inflammation. In contrast, most authors agree that aging results in an increase in the basal level of endothelial cell proliferation (Sholley and Cotran, 1976; Li et al., 1997; McCaffrey et al., 1988). Aorta transplantation experiments between young and old rats suggest that hyper proliferation of vascular smooth muscle cells might be a cell autonomous phenomenon, rather than environment-driven (Hairiri et al., 1986). Similar assessments have not been made with regard to endothelial cells, and while dysregulation has been observed at the level of signal transduction pathways, including Ras/ERK, AKT and Zap 70 (Hoffmann et al., 2001; Hutter et al., 2000; Pahlavani et al., 1998), a role for extrinsic, blood-borne factors has not been ruled out.

Serum T-kininogen (T-KG) levels increase dramatically with age in rats (Sierra et al., 1989, 1992), and a similar observation has been made for HMW-kininogen in both humans (Kleniewski and Czokalo, 1991) and rats (Sierra, 1995), suggesting that this increase is a general phenomenon

*Abbreviations:* hTERT, protein component of human telomerase; RAEC, Rat aorta endothelial cells; T-KG, T-kininogen; PD, PD098056; Bis, Bisindoleylmaleimide; Ly, Ly294002; Des-Arg, Des-Arg<sup>9</sup>-leu<sup>8</sup>-BK; HOE, HOE 140; Ram, Ramiprilat

<sup>\*</sup> Corresponding author at: Biology of Aging Program, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Ave., Suite 2C231, Bethesda 20892, USA. Tel.: +1 301 496 6402; fax: +1 301 402 0010.

E-mail address: Sierraf@nia.nih.gov (F. Sierra).

associated with aging. When expressed in BALB/c 3T3 fibroblasts, T-KG inhibits cell proliferation (Torres et al., 2001) and ERK activity (Torres et al., 2000). However, when the same fibroblasts are exposed to exogenous T-KG, both proliferation and ERK activity are increased instead (Aravena et al., 2005). These observations suggest that the age-related increase in serum kininogens might play a role in modulating the changes in proliferative capacity of blood-exposed cells, including endothelial cells. Both HMW-KG and LMW-KG have been shown to be angiogenic, and capable of promoting endothelial cell proliferation and motility (Hayashi et al., 2002; Colman et al., 2003). Furthermore, kininogens are precursors of kinins, vasoactive peptides that also promote endothelial cell proliferation through kinin receptors, primarily B2 (Colman et al., 2003; Seegers et al., 2003). In the case of HMW-KG, release of the kinin moiety leaves behind an entity called HKa, composed of a heavy and a light chain held together by a single disulfide bridge, and which has strong antiangiogenic properties, thus opposing the effect of both kinins and their precursors (reviewed in Guo and Colman, 2005). In contrast, neither LMW-KG nor T-KG gives rise to anti-angiogenic moieties after release of their kinins. Thus, these molecules are likely to be only pro-angiogenic in vivo.

We hypothesize that the age-dependent increase in both T-KG and kinins (Pérez et al., 2005) could play a role in the increased endothelial cell proliferation observed in aged individuals. Since endothelial cells do not themselves produce significant amounts of kininogens, we used exogenously added purified T-KG, and our results indicate that T-KG induces endothelial cell proliferation, and this effect is accompanied by an increase in ERK and AKT activities. In contrast, T-KG inhibits the responsiveness of these cells to the stimulus provided by kinins (Leiva-Salcedo et al., 2002). These observations suggest a possible role for serum kininogens in the dysregulation of vascular system physiology and function that occurs during aging, both in rats and in humans.

#### 2. Materials and methods

#### 2.1. Reagents

Antibodies to ERK, P-ERK, AKT and P-AKT were obtained from Cell Signaling. Anti B2 kinin receptor, and horseradish peroxidase-conjugated secondary antibodies were purchased from Transduction Laboratories. Anti-Von Willebrand factor, anti-HMW-KG antibodies, HOE 140, Des-Arg-BK, T-kinin and Bradykinin were from Sigma. The anti-bradykinin antibody used in the RIA was donated by Dr. Kasuaki Shimamoto (Sapporo Medical University, Sapporo, Japan), and the anti T-KG antibody was developed and characterized in our laboratory. All commercial antibodies were used at the concentration recommended by the manufacturer. The inhibitors PD098056, Bisindoleylmaleimide, Ly294002 and H89 were obtained from Calbiochem. [<sup>3</sup>H]-TdR was from NEN. D-MEM, Trypsin/EDTA and penicillin/streptomycin (10,000 IU/ml) were obtained from Gibco BRL, FBS serum was from Cellgro.

### 2.2. Purification of T-KG

T-KG was purified from rat serum as previously described (Leiva-Salcedo et al., 2002). Briefly, serum was collected from Brown Norway rats (Katholiek strain) 24 h after LPS injection (2 mg/kg). This strain of rats carries a point

mutation in the K-KG gene that eliminates the secretion of both HMW- and LMW-KG into the serum, and thus, T-KG is the only kininogen present in the starting material (Damas, 1996). T-KG was purified from total serum by affinity chromatography on carboxymethyl-papain-agarose. Eluted proteins in the peak at  $A_{280}$  were tested for cysteine proteinase inhibitory activity using 10 nM papain and Z-Arg-Arg-NH Mec (Sigma, 1 nM final) as a substrate.

#### 2.3. Expression and purification of recombinant T-KG

The T-KG-GST fusion protein was obtained from *Escherichia coli* BL21 cells transformed with pGEX-4T constructs encoding T-KG. After induction with IPTG 100  $\mu$ M for 5 h at an OD<sub>600</sub> of 0.7, bacteria were pelleted, lysed, sonicated and centrifuged at 14,000 × *g*, 15 min. The bacterial supernatants were incubated with glutathionine–Sepharose (Amersham) for 1 h at 4 °C and GST fusion protein was eluted with 100 mM Tris–HCl pH 8.0 containing 150 mM NaCl and 10 mM glutathione. The eluted proteins were dialyzed into PBS pH 7.4 and T-KG was positively identified using anti-T-KG antibody. cjun-GST fusion protein was used as a negative control.

#### 2.4. Flow cytometry and binding assays

Endothelial cells  $(1 \times 10^3 \text{ cells/ml})$  were incubated on ice with FITC conjugated T-KG (10 µg/ml) for 30 min in the dark at 4 °C in iced-cold PBS containing 0.1% FBS. Cells were then pelleted, washed twice and resuspended in sterile PBS. For competitive FACS analysis, after 10 min of binding to T-KG-FITC, cells were washed and incubated with bradykinin (BK, 100 µg/µl) or unlabeled T-KG (100 µg/µl), for another 30 min. Binding was evaluated by FACscan flow cytometry (Cell Quest, BD Biosciences San Diego, CA) using WinMDI 2.8 software. The number of T-KG receptors and kinetics parameters were obtained through a spectrofluorometric assay, where free T-KG concentrations were measured using a standard curve. Endothelial cells were harvested with PBS/EDTA and  $2 \times 10^5$  cells/ml were incubated with T-KG-FITC (in a range of 0.1-100 µg/ml) for 30 min on ice. The free ligand was separated by centrifugation (10,000  $\times$  g, 2 min, 4 °C), and both the pellet and supernatant were adjusted to 110 µl using PBS/SDS 10%. Saturation, nonspecific binding and competition assays were performed to establish the specificity of the binding. The kinetics parameters were obtained using Scatchard and Lineweaver-Burk plots (Foreman and Johansen, 2004).

# 2.5. Cell culture and isolation of primary endothelial cells from rat aorta (RAEC)

EAhy 926 cells (a gift of Dr. Earl Harrison, MCP-Hahnemann University, Philadelphia, PA), were grown in D-MEM containing 10% FBS, 10 U/ml gentamycin (Gibco BRL) and supplemented with HAT in a humidified 5%  $CO_2$  atmosphere at 37 °C.

Rat aorta endothelial cells (RAEC) were purified by a modification of the method described by Suschek et al. (1993). Briefly, aorta from male Sprague–Dawley rats (180 g) was removed, opened longitudinally and the tissue was incubated in D-MEM containing 10% FBS and 100 µg/ml penicillin/strepto-mycin in the presence of 1 mg/ml collagenase for 30 min at room temperature in an orbital shaker. Then the cells were centrifuged at 1900 × g for 5 min, and the pellet was resuspended in D-MEM containing 10% FBS plus 5% calf serum, heparin (50 µg/ml) and bFGF (10 ng/ml). Cells were seeded on a 60 mm-plate previously coated with fibronectin (10 µg/ml). After 1 h, viable endothelial cells were attached to the matrix, and unattached cells were removed by washing. Cells were further passaged (1:3) every 4 days on dishes previously coated with 2% gelatin, and were used before the 4th passage. RAEC cells were characterized by staining with antibodies against Von Willebrand factor and kinin B2 receptor (Cines et al., 1998). In all experiments, cells were seeded at  $1 \times 10^4$  cells/cm<sup>2</sup> and grown in a humidified 5% CO<sub>2</sub> atmosphere at 37 °C.

#### 2.6. Preparation of hTERT-RAEC cells

Semi-confluent primary RAEC cells were infected at a m.o.i. of 1:1 with a retroviral vector containing the protein portion of the human telomerase gene (pBNhEst2-hTERT-Neo, a gift from Dr. C. Sell, Lankenau Institute for Medical

### V. Pérez et al.

Research, Wynnewood, PA). After selection in Endothelial Cell Basal Medium (EBM) containing 10% FBS and 100  $\mu$ g/ml G418 (Gibco BRL), 6 colonies that continued to grow past the age of senescence for the culture were selected and further grown and characterized. Identity of the cell lines as endothelial in origin was assessed by staining with anti Von Willebrand factor and kinin B2 receptor antibodies as above. In contrast to primary RAEC cells, hTERT-RAEC appear to grow indefinitely, and maintain their endothelial characteristics even when grown in the absence of any matrix components (data not shown).

#### 2.7. Cell counting and proliferation assays

Cells were seeded at  $1 \times 10^4$  cells/cm<sup>2</sup> in 6-well plates, and cultured in D-MEM containing 10% FBS for 24 h. The medium was changed to D-MEM with 0.5% FBS for another 24 h, T-KG (1 µg/ml) was added and the incubation continued for a further 24 h. The total number of cells was measured at the end of this period in a Coulter counter. For the proliferation assay, cells were seeded in 96-multiwell plates (1 × 10<sup>3</sup> cells/well), and cultured as described above. T-KG (1 µg/ml, unless otherwise indicated) was added and the incubation continued for a further 18 h, at which time [<sup>3</sup>H]-TdR (2 nCi/µl) was added and incubation was continued for 6 additional hours. Cells were lysed with 10% trichloroacetic acid (TCA). The acid-insoluble material was collected on glass microfiber filters (GF-C), washed with 5% TCA and ethanol, and then the filters were dried and counted in triplicate in a liquid scintillation counter (Tracor Analytic Delta 300).

#### 2.8. Kinin radio immuno assay (RIA)

Free kinins present in the cell supernatants were measured as described (Pérez et al., 2005).

### 2.9. Statistical analysis

All experiments were done at least in triplicate. Data are expressed as mean  $\pm$  S.E. and were analyzed by the non-parametric test of Mann–Whitney. Differences were considered statistically significant if p < 0.05.

#### 3. Results

### 3.1. Exogenous T-KG induces endothelial cell proliferation

To test the possible effects of exogenous T-kininogen on endothelial cell proliferation, EAhy 926 cells were serum starved for 24 h and then, a variable amount of purified T-KG was added to the medium for 24 h. The concentration of T-KG used  $(0.25-6.6 \,\mu\text{g/ml})$  is approximately 2 orders of magnitude below the physiological concentration of the protein in normal rat serum (Raymond et al., 1996). However, most of this T-KG exists in the serum as a multimolecular complex (E.L. and F.S., unpublished observations), and we estimate that the concentration of free T-KG in old animals is only approximately 10–20 µg/ml, close to the range of concentrations used here. Incorporation of [<sup>3</sup>H]-TdR was assessed during the last 6 h of incubation by measuring TCA precipitable counts. Fig. 1A indicates that exogenous T-KG induces [<sup>3</sup>H]-TdR incorporation in these cells in a strictly dose-dependent manner, up to a concentration of 1 µg/ml. This concentration of T-KG was used in all subsequent experiments. To test that this really represents cell proliferation, we did direct cell counting, 24 h after addition of 1 µg/ml of purified T-KG. Fig. 1B shows that T-KG increased the number of cells to almost twice, relative to control. To confirm that this was not due to a contaminant in the preparation, Fig. 1B shows that a similar effect is obtained in



Fig. 1. Exogenous T-KG induces endothelial cell proliferation. (A) Dosedependence of the effect of T-KG on endothelial cell proliferation. EAhy 926 cells were seeded and cultured as described. T-KG was added at the concentrations indicated for an additional 24 h and cell proliferation was measured by  $[^{3}H]$ -TdR incorporation (2nCi/µl) during the last 6 h of the assay. The results are expressed relative to controls without T-KG. (B) EAhy 926 cells starved in 0.5% FBS for 24 h were treated with purified T-KG (1 µg/ml, T-KG) or fusion proteins (1 µg/ml, either T-KG-GST or cjun-GST) for an additional 24 h. Cells were counted using a Coulter counter, and the results are expressed as number of cells/cm<sup>2</sup>. (C) Different endothelial cells (EAhy 926, primary endothelial (RAEC) or hTERT-RAEC) were exposed to T-KG (1 µg/ml) as indicated for 24 h. Proliferation was assessed as above. As a control, [<sup>3</sup>H]-TdR incorporation in response to 10% FBS was also measured in each cell line. The incorporation observed in the absence of either T-KG or FSB was assigned a value of 1, and incorporation in the presence of T-KG or FBS is presented relative to that control. The results are the mean from 4 independent experiments. In all cases, statistical significance was established by the Mann-Whitney test, where  $p^* < 0.05$ .

the presence of recombinant T-KG-GST fusion protein  $(1 \mu g/ml)$ , but not when we used cjun-GST fusion protein as a control. Fig. 1C indicates that the effect is not unique to EAhy 926 hybridoma cells, since an approximately 2–3-fold increase in [<sup>3</sup>H]-TdR incorporation was also observed in primary cultures of rat aorta cells (RAEC), and in hTERT-RAEC, a stable cell line prepared by retroviral infection of rat aorta endothelial cells with hTERT. The hTERT-RAEC cells retain a differentiated phenotype, as assessed by staining with anti-Von Willebrand factor, as well as anti-B2 kinin receptors (data not shown). Exposure of hTERT-RAEC cells to  $1 \mu g/ml$  T-KG leads to an increase in [<sup>3</sup>H]-TdR incorporation comparable to that observed in the other cell types, and also quantitatively comparable to that observed after serum stimulation of quiescent hTERT-RAEC cells (Fig. 1C). Therefore, all subsequent experiments were performed in hTERT-RAEC cells, since they represent a more easily manipulated functional model of endothelial cells.

# 3.2. T-KG binds to endothelial cells

As a first approach to explore the effect of T-KG on endothelial cells, we measured its binding at 4 °C, using flow cytometry. Fig. 2A shows that T-KG (10  $\mu$ g/ml) binds to endothelial cells, and this binding is completely displaced by unconjugated T-KG (100  $\mu$ g/ml) or by BK (100  $\mu$ g/ml). Furthermore, Fig. 2B shows that binding of T-KG to endothelial cells is dose-dependent and saturable (Fig. 2B inset). A Scatchard plot (Fig. 2B) suggests the presence of two classes of binding sites. Using the Lineweaver–Burk plot of reciprocal doubles, we find that hTERT-RAEC endothelial cells have approximately 74.6 ± 19.6 high affinity binding sites/cell, with a dissociation constant of 10.8 ± 3.8  $\mu$ M. Low affinity binding



Fig. 2. T-KG binds to endothelial cells. (A) Specificity of binding. Endothelial cells  $(1 \times 10^3 \text{ cells/ml})$  were incubated in the presence of  $10 \,\mu\text{g/ml}$  FITC-conjugated T-KG for 30 min at 4 °C. The cells were washed, resuspended in flow cytometry buffer, and analyzed in a FACScan cytometer as described in Section 2. The mean relative fluorescence was analyzed using WinMDI 2.8 software. Unlabeled T-KG ( $100 \,\mu\text{g/}\mu\text{l}$ ) or Bradykinin ( $100 \,\mu\text{g/}\mu\text{l}$ ) were used as competitors. (B) Binding and kinetic parameters. Inset: The dose dependency of T-KG binding was assessed by using different doses of FITC-conjugated T-KG, and binding was measured spectrofluorometrically as described. Kinetic parameters were obtained using both the Scatchard and Lineweaver–Burk plots. The results are the mean of 3 independent assays.



Fig. 3. The induction of endothelial cell proliferation depends on the time of exposure to exogenous T-KG. hTERT-RAEC cells were cultured as described, and incubated in the presence of T-KG (1 µg/ml) for different times as indicated. After this time, cells were washed twice with warm PBS and then the cultures were continued in 0.5% FBS until a total of 24 h in culture after the initial addition of T-KG. (<sup>3</sup>H)-TdR incorporation was measured during the last 6 h of incubation as described above. (A) Schematic representation of the experimental approach. (B) Cell proliferation was measured as described. The results are expressed relative to the control (Co), which received no T-KG, but was treated exactly as the experimental samples (<sup>\*</sup>p < 0.05).

sites (approximately  $600 \pm 44$  binding sites/cell, with a  $K_{\rm d} = 34.3 \pm 8 \ \mu$ M), were also detected.

# 3.3. The induction of endothelial cell proliferation depends on the time of exposure to exogenous T-KG

To determine the minimal time necessary for T-KG to exert its action, we incubated hTERT-RAEC cells for different times in the presence of 1  $\mu$ g/ml T-KG. After washing the cells twice to eliminate any unbound T-KG, cultures were replenished with normal 0.5% FBS-containing medium, and incubation was continued for a total of 24 h from the initial addition of T-KG (Fig. 3A). Incorporation of [<sup>3</sup>H]-TdR was measured as described above, and the results shown in Fig. 3B indicate that a minimum of 4 h of continuous presence of T-KG is necessary before an effect can be observed. Exposure of cells for shorter times (up to 2 h) did not result in induction of cell proliferation.

# 3.4. Induction of cell proliferation requires both types of kinin receptors

T-KG is a precursor of T-kinin, and it has been shown to bind as such to kinin receptors (Morbidelli et al., 1998). However, its effect on these receptors is not known. To assess whether or not the effects of T-KG on cell proliferation are mediated by kinin receptors, we measured cell proliferation in the presence of 2  $\mu$ M HOE 140 (a B2 receptor antagonist) or 1  $\mu$ M Des-Arg<sup>9</sup>-leu<sup>8</sup>-BK (a B1 receptor antagonist). The



Fig. 4. Induction of cell proliferation requires both types of kinin receptors. (A) hTERT-RAEC cells were seeded and cultured as usual. Kinin receptor antagonists (2 µM HOE-140 for B2 and 1 µM Des-Arg9-BK for the B1 receptor) were added 30 min before the addition of T-KG (1 µg/ml) for 24 h. Cell proliferation was assessed as described above. Co, control cells (untreated); FBS, cells treated with 10% FBS. The asterisks denote statistical significance to a p < 0.05, relative to samples treated with T-KG in the absence of antagonists. (B) Cells were cultured as before in the presence of T-KG (1 µg/ml), and free kinin levels were determined by RIA after 24 h in culture. Control, cells without any treatment; Ram, Ramiprilat (1 µM); EtOH, serum samples were precipitated with ethanol during collection, and kinins were measured in the supernatant. (C) The integrity of the precursor T-KG was measured by Western blot analysis of conditioned media at different times in culture as indicated. Co, conditioned medium from cells not exposed to T-KG. The arrowhead on the right side of the figure indicates the expected size of T-KG should kinin been released from the precursor.

results shown in Fig. 4A indicate that cell proliferation in response to exogenous addition of T-KG requires both types of receptor. As a control, when used alone, the antagonists by themselves did not have a significant effect on proliferation.

Since kinins are known to induce endothelial cell proliferation (Seegers et al., 2003), one possible explanation for our results is that T-kinin might have been released into the culture medium from the precursor T-KG. By using a sensitive RIA assay to measure free kinins in the culture medium, we were unable to detect an increase in kinin levels in the T-KG-

containing conditioned medium (Fig. 4B). Because of the extreme instability of kinins, these measurements were done at different times, and kinins were stabilized using ramiprilat, an ACE inhibitor that also strongly inhibits kininase activities (kinin-degrading enzymes). Stabilization after collection was also attempted by using an ethanol precipitation protocol (Pueyo et al., 1996), but still, we detected no T-KG-dependent increase in kinins in the ethanol supernatants (Fig. 4B). Furthermore, Fig. 4C indicates that neither the MW, nor the mass of the added T-KG is affected by its addition to the culture medium. Release of T-kinin would have decreased the MW of the precursor by approximately 10 kDa. Therefore, we conclude that T-kinin is not released from its precursor under our experimental conditions, and thus the proliferative effects we observe are due to T-KG itself.

# 3.5. The induction of cell proliferation requires several signal transduction pathways

Binding of T-KG to the cells is competed by free kinins (Fig. 2) and the proliferative effect requires kinin receptors (Fig. 4A). Kinin receptors have been shown to activate a large network of signal transduction pathways, and we used a pharmacological approach to establish which pathways are required for the proliferative effect. In all cases, inhibitors were added 30 min before T-KG, and proliferation was then measured 24 h later as described. As a control, we assessed toxicity of the inhibitors by cell counting at the end of the experiment. None of the treatments induced cell loss by more than 10%, compared to FBS alone (data not sown). The results shown in Fig. 5 indicate that the induction of cell proliferation by exogenous T-KG requires, at the least, ERK, PI3K, PKC and PKA. These results suggest a complex mechanism of induction of cell proliferation, that includes the kinin receptors, and activation of several signal transduction pathways known to be located downstream of the receptor: ligand binding event.



Fig. 5. Induction of cell proliferation requires the activity of several signal transduction pathways. The experimental design was exactly as described in Fig. 4, except that kinin receptor antagonists were replaced by inhibitors of different signal transduction pathways: PD098056 (1  $\mu$ M, MEK 1/2 inhibitor), Ly-294002 (10  $\mu$ M, PI3Kinase inhibitor), Bisindolylmaleimide (100 nM, PKC inhibitor) and H89 (1  $\mu$ M, PKA inhibitor). DMSO alone, T-KG plus DMSO and each of the inhibitors in the absence of T-KG were used as controls (data not shown) (\*p < 0.05), relative to samples treated with T-KG in the absence of inhibitors.

### V. Pérez et al.

# 3.6. Exogenous T-KG induces AKT and ERK activation in endothelial cells

The ERK and AKT pathways are the signal transduction mechanisms most traditionally associated with induction of cell migration and proliferation, and inhibition of either of these pathways eliminates the proliferative effect of T-KG. Therefore, it was of interest to establish the kinetics of activation of these two pathways in response to T-KG exposure. We observed activation of AKT, showing a single peak at 15 min after T-KG addition (Fig. 6A). We also observed a rapid biphasic activation of ERK, with a first peak at 5 min after T-KG addition, and a second, lower but sustained peak that starts at approximately 60-120 min (Fig. 6B). Because this second peak is not observed when endothelial cells are induced with kinins (Leiva-Salcedo et al., 2002), we chose to assess its relative importance for the proliferative effect. For this, we repeated the proliferative assay in the presence of PD098056. However, this time the inhibitor was added 15 min after the addition of T-KG (i.e., after the first



Fig. 6. Exogenous T-KG induces AKT and ERK activation. Cells were incubated with T-KG (1  $\mu$ g/ml) for different times as shown. Cellular extracts were resolved in a 10% SDS-PAGE gel and blots were assayed for P-AKT and total AKT (Panel A), or P-ERK1/2 and total ERK1/2 (Panel B). Activation is expressed as a ratio between phosphorylated and non-phosphorylated proteins relative to the controls (N = 4 for ERK, N = 5 for AKT).



Fig. 7. Cell proliferation induced by T-KG is abolished by inhibition of the second peak of ERK1/2 activity. (A) Cells were seeded as described in Fig. 1, and half of the cells were treated with 1  $\mu$ M PD 098056 15 min after addition of T-KG (15 min/PD). Proliferation was measured 24 h later as described. Co, cells without any additions; FBS, cells treated with 10% FBS. \*Statistically significant (p < 0.05) difference relative to samples treated with T-KG in the absence of PD0980056. (B) As a control of the effectiveness of the inhibitor, ERK activity was measured by Western blot at different times after addition of T-KG, both in the presence or absence of PD0980056, added 15 min after T-KG.

peak of ERK activity). The results shown in Fig. 7 indicate that under these conditions, the proliferative effect of T-KG is completely abrogated, suggesting that the second peak of ERK activity is important and necessary for the proliferative effect of T-KG on endothelial cells. This observation provides further evidence suggesting that the proliferative effect of T-KG is not mediated by the release of free kinins. Furthermore, this result is consistent with data presented in Fig. 3, showing that a short exposure of cells to T-KG is not sufficient to trigger cell proliferation.

# 4. Discussion

Endothelial cell function declines with age, leading to a functional decline in several hemodynamic parameters (Marin, 1995; Challah et al., 1997). Among the age-related changes in vascular physiology, increased endothelial cell proliferation can lead to hyperplasia as well as angiogenesis. Several reports have indicated an increased turnover of both smooth muscle and endothelial cells in regions susceptible to atherosclerosis (Okuda et al., 2000; Minamino et al., 2002). Phillips et al. (1994) described that primary endothelial cells derived from old rats respond better than those from young rats to the proliferative stimulus of serum, while Challah et al. (1997) described an increase in the number of circulating endothelial cells in old rats, suggesting an increase in the rate of endothelial cell turnover with aging. These findings were not confirmed by

Cortés et al. (2002) who found that arterial cell proliferation was similar in young and old animals. The mechanisms responsible for this age-related increase in proliferation are not known, and our results suggest that the increase in serum levels of kininogens observed in old rats and humans could play a role. Interestingly, we have previously shown that expression of T-KG in mouse fibroblasts inhibits cell proliferation (Torres et al., 2000, 2001), while exogenous addition of T-KG leads to increased proliferation instead (Aravena et al., 2005). Thus, at least in fibroblasts, the effect of T-KG can be diametrically opposite, depending exclusively on the mode of administration (endogenous expression versus exogenous addition).

It has been described that both kininogens and their metabolite, kinins, can induce angiogenesis and endothelial cell proliferation (Morbidelli et al., 1998; Parenti et al., 2001). The data presented in Fig. 4 suggests that free kinins are not produced to a large extent in our system. This is not surprising, since T-KG is a unique kininogen, which is not susceptible to tissue kallikreins present in endothelial cells, and T-kininogenases have not been described in these cells. Furthermore, the proliferative effect of kinins has only been observed at high concentrations, and even if all the T-KG present in our experiments was fully converted to T-kinin, the level of the peptide would only reach 15 nM, a concentration at least one order of magnitude lower than that used to induce proliferation. Finally, the activation of ERK by T-KG (Fig. 6) is kinetically different from that elicited by kinins, and the proliferative effect induced by T-KG requires the second peak of ERK activation, which is not present in kinin-treated cells. In fact, we have shown that T-KG actually inhibits ERK activation in response to kinins (Leiva-Salcedo et al., 2002; Pérez et al., 2005), probably through competition for the same receptors in the cell surface. Taken together, it appears most likely that T-KG, like its counterparts HMW-KG and LMW-KG, induces endothelial cell proliferation as such, without needing to release kinins. The fact that this effect requires kinin receptors is consistent with reports indicating that HMW-KG (the precursor of bradykinin) can bind to these receptors, at least in vitro (Hasan et al., 1994).

Binding of kinins to either of its receptors leads to the activation of a complex array of signal transduction processes. Consistent with this, our studies indicate that the proliferative effect of T-KG requires, at the least, the activity of ERK, AKT, PKC and PKA. It should be mentioned that the parameter we have measured, proliferation after 24 h, is complex in nature and could well require the coordinate activity of all these pathways. Using the SW-480 cell line, Graness et al. (1998) observed that the proliferative response induced by bradykinin involves PKCE, PI3K and ERK, and the authors suggest the involvement of a trans-activation mechanism for the activation of ERK (Marinissen and Gutkind, 2001). Indeed, many G protein coupled receptors appear to activate the ERK pathway indirectly, through a mechanism that requires a membrane metalloprotease, which activates tyrosine kinase-containing receptors (Zwick et al., 1999; Mukhin et al., 2003). Intriguingly, we have previously shown (Aravena et al., 2005) that in fibroblasts, the induction of cell proliferation by exogenous T-KG is independent of kinin receptors, as determined by susceptibility to the same antagonists used here. It is therefore likely that these differences might be due to variation in the number and type of receptors each cell type expresses on its surface.

The data presented here suggests that the age-related increase in serum T-KG levels could lead to an increase in the proliferative capacity of endothelial cells, thus potentially playing a role in angiogenesis in the old. In considering the physiological implications of our findings, it is worth mentioning that the amount of exogenous T-KG we have used in our experiments is well below physiological concentrations (normally  $1255 \pm 57 \ \mu$ g/ml of blood in young rats (Raymond et al., 1996). Thus, our experiments are not done under pharmacological conditions. On the other hand, the effects we have observed were obtained with concentrations that are so much below physiological, that it is possible to argue against their relevance from that side as well. We would argue that the in vivo concentration of free T-KG (that is, T-KG not associated in macromolecular complexes) is close to the concentration used here, and it is only this free T-KG that has the biological activity. Indeed, formation of multimolecular complexes in vivo could buffer the physiological effects of T-KG. Our unpublished data (E.L. and F.S., unpublished observations) indicate that free T-KG does indeed exist in the serum of old Fisher 344 rats, to a larger extent than observed in younger animals. In all cases, however, free T-KG appears to represent only a small percentage of the total (between 1 and 5% in different animals), and therefore, the concentration of free T-KG in rat serum is likely to be within the range used in these experiments. Thus, at least in old individuals, it is likely that free T-KG can play a role in the observed increase in proliferation of endothelial cells. We propose that, through its effects on endothelial cells, serum T-KG might influence vascular functions, including atherosclerotic plaque formation and increased angiogenesis. Since we have previously shown that serum T-KG levels increase with age in several strains of rats, our results further imply this molecule as a relevant player in age-related vascular pathology.

# Acknowledgements

The authors want to thank Drs. Lisa Laury-Kleintop, Andrew Quest, Claudio Torres and Victoria Velarde for helpful discussions and critical comments on the manuscript. We thank Drs. Christian Sell and Kasuaki Shimamoto for reagents. This research was funded by FONDECYT grants 2000038, 2010071 and 1010615, FONDAP 15010006 and NIH/NIA grant R01 AG 13902.

### References

- Aravena, M., Pérez, C., Pérez, V., Acuña-Castillo, C., Gómez, C., Leiva-Salcedo, E., Nishimura, S., Sabaj, V., Walter, R., Sierra, F., 2005. T-kininogen can either induce or inhibit proliferation in BALB/c 3T3 fibroblasts, depending on the route of administration. Mech. Ageing Dev. 126, 399–406.
- Challah, M., Nadaud, S., Philippe, M., Battle, T., Soubrier, F., Corman, B., Michel, J.B., 1997. Circulating and cellular markers of endothelial dysfunction with aging in rats. Am. J. Physiol. 273 (Heart Circ. Physiol. 42), H1941–H1948.

- Cines, D.B., Pollak, E.S., Buck, C.A., Loscalzo, J., Zimmerman, G.A., McEver, R.P., Pober, J.S., Wick, T.M., Konkle, B.A., Schwartz, B.S., Barnathan, E.S., McCrae, K.R., Hug, B.A., Schmidt, A.M., Stern, D.M., 1998. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91, 3527–3561.
- Colman, R.W., Pixley, R.A., Sainz, I.M., Song, J.S., Isordia-Salas, I., Muhamed, S.N., Powell Jr., J.A., Mousa, S.A., 2003. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J. Thromb. Haemost. 1, 164–170.
- Cortés, M., Díez-Juan, A., Pérez, P., Pérez-Roger, I., Arrollo-Pellier, R., Andrés, V., 2002. Increased early atherogenesis in young versus old hypercholesterolemic rabbits by a mechanism independent of arterial cell proliferation. FEBS Lett. 522, 99–103.
- Cristofalo, V.J., Volker, C., Francis, M.K., Tresini, M., 1998. Age-dependent modifications of gene expression in human fibroblasts. Crit. Rev. Eukaryot. Gene Expr. 8, 43–80.
- Damas, J., 1996. The brown Norway rats and the kinin system. Peptides 17, 859–872.
- Foreman, J., Johansen, T., 2004. Textbook of Receptor Pharmacology, 2nd ed. CRC press.
- Graness, A., Adomeit, A., Heinze, R., Wetzker, R., Liebmann, C., 1998. A novel mitogenic signaling pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential activation of a Gq/11 protein, phosphatidylinositol 3-kinase beta, and protein kinase C epsilon. J. Biol. Chem. 273, 32016–32022.
- Guo, Y.L., Colman, R.W., 2005. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J. Thromb. Haemost. 3, 670–676.
- Hairiri, R.J., Alonso, D.R., Hajjar, D.P., Coletti, D., Wecksler, B., 1986. Aging and arteriosclerosis. I. Development of myointimal hyperplasia after endothelial injury. J. Exp. Med. 164, 1171–1178.
- Hasan, A., Cines, D., Zhang, J., Schmaier, H., 1994. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. J. Biol. Chem. 269, 31822–31830.
- Hayashi, I., Amano, H., Yoshida, S., Kamata, K., Kamata, M., Inukai, M., Fujita, T., Kumagai, Y., Furudate, S., Majima, M., 2002. Suppressed angiogenesis in kininogen-deficiencies. Lab. Invest. 82, 871–880.
- Hoffmann, J., Haendeler, J., Aicher, A., Rössig, Vasa, M., Zeiher, A.M., Dimmeler, S., 2001. Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Cir. Res. 89, 709– 715.
- Holt, P.R., Yeh, K.Y., 1988. Colonic proliferation is increased in senescent rats. Gastroenterology 95, 1556–1563.
- Hutter, D., Yo, Y., Chen, W., Liu, P., Holbrook, N., Roth, G., Liu, Y., 2000. Agerelated decline in Ras/ERK mitogen-activated protein kinase cascade is linked to a reduced association between Shc and EGF receptor. J. Gerontol. A (Biol. Sci. Med. Sci.) 55, B125–B134.
- Kleniewski, J., Czokalo, M., 1991. Plasma kininogen concentration: the low level in cord blood plasma and age dependence in adults. Eur. J. Haematol. 46, 257–262.
- Leiva-Salcedo, E., Pérez, V., Acuña-Castillo, C., Walter, R., Sierra, F., 2002. Tkininogen inhibits kinin-mediated activation of ERK in endothelial cells. Biol. Res. 35, 287–294.
- Li, Z., Cheng, H., Lederer, W.J., Froehlich, J., Lakatta, E.G., 1997. Enhanced proliferation and migration and altered cytoskeletal proteins in early passage smooth muscle cells from young and old rat aortic explants. Exp. Mol. Pathol. 64, 1–11.
- Marin, J., 1995. Age-related changes in vascular responses: a review. Mech. Ageing Dev. 79, 71–114.
- Marinissen, M.J., Gutkind, J.S., 2001. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci. 22, 368–376.
- McCaffrey, T., Nicholson, A., Szabo, P., Weksler, M., Weksler, B., 1988. Aging and arteriosclerosis. The increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity. J. Exp. Med. 4, 1171–1178.
- Minamino, T., Miyauchi, H., Yoshida, T., Ishida, Y., Yoshida, H., Komuro, I., 2002. Endothelial cell senescence in human atherosclerosis: role of telomeres in endothelial dysfunction. Circulation 105, 1541–1544.

- Morbidelli, L., Parenti, A., Giovannelli, L., Granger, H.J., Ledda, F., Ziche, M., 1998. B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects. Br. J. Pharmacol. 124, 1286–1292.
- Mukhin, Y.V., Garnovsky, E.A., Ullian, M.E., Garnovskaya, M.N., 2003. Bradykinin B2 receptor activates extracellular signal-regulated protein kinase in mIMCD-3 cells via epidermal growth factor receptor transactivation. J. Pharmacol. Exp. Ther. 304, 968–977.
- Okuda, K., Khan, M.Y., Skurnick, J., Kimura, M., Aviv, H., Aviv, A., 2000. Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis 152, 391–398.
- Pahlavani, M.A., Harris, M.D., Richarson, A., 1998. Activation of p21ras/ MAPK signal transduction molecules decreases with age in mitogenstimulated T cells from rats. Cell. Immunol. 185, 39–48.
- Parenti, A., Morbidelli, L., Ledda, F., Granger, H.J., Ziche, M., 2001. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 15, 1487–1489.
- Pérez, V., Velarde, V., Acuña-Castillo, C., Gómez, C., Nishimura, S., Sabaj, V., Walter, R., Sierra, F., 2005. Increased kinin levels and decreased responsiveness to kinins during aging. J. Gerontol. A (Biol. Sci. Med. Sci.) 60, 984–990.
- Phillips, G.D., Stone, A.M., Schultz, J.C., Jones, B.D., Knighton, D.R., 1994. Proliferation of wound derived capillary endothelial cells: young versus aged. Mech. Ageing Dev. 77, 141–148.
- Prakash, K., Pirozzi, G., Elashoff, M., Munger, W., Waga, I., Dhir, R., Kakehi, Y., Getzenberg, R.H., 2002. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc. Natl. Acad. Sci. U.S.A. 99, 7598–7603.
- Pueyo, M.E., N'Diaye, N., Michael, M.B., 1996. Angiotensin II-elicited signal transduction via AT1 receptors in endothelial cells. Br. J. Pharmacol. 118, 79–84.
- Raymond, P., Wang, H., Blais Jr., C., Decarie, A., Adam, A., Morais, R., 1996. Chloramphenicol and the inflammatory response in the rat. Upregulation of the gene for T2-kininogen in liver. J. Pharmacol. Exp. Ther. 278, 934–940.
- Seegers, H.C., Hood, V.C., Kidd, B.L., Cruwys, S.C., Walsh, D.A., 2003. Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation. J. Pharmacol. Exp. Ther. 306, 8–12.
- Sholley, M.N., Cotran, R.S., 1976. Endothelial DNA synthesis in the microvasculature of rat skin during the hair growth cycle. Am. J. Anat. 147, 243– 254.
- Sierra, F., 1995. Both T- and K-kininogens increase in the serum of old rats but by different mechanisms. Mech. Ageing Dev. 84, 127–137.
- Sierra, F., Fey, G.H., Guigoz, Y., 1989. T-kininogen gene expression is induced during aging. Mol. Cell. Biol. 9, 5610–5616.
- Sierra, F., Coeytaux, S., Juilerrat, M., Ruffieux, C., Gauldie, J., Guigoz, Y., 1992. Serum T-kininogen levels increase two to four months before death. J. Biol. Chem. 267, 10665–10669.
- Suschek, C., Rothe, H., Fehsel, K., Enczmann, J., Kolb-Bachofen, V., 1993. Induction of a macrophage-like nitric oxide synthase in cultured rat aortic endothelial cells. IL-1 beta-mediated induction regulated by tumor necrosis factor-alpha and IFN-gamma. J. Immunol. 151, 3283–3291.
- Torres, C., Li, M., Walter, R., Sierra, F., 2000. Modulation of the ERK pathway of signal transduction by cysteine proteinase inhibitors. J. Cell Biochem. 80, 11–23.
- Torres, C., Li, M., Walter, R., Sierra, F., 2001. T-kininogen inhibits fibroblast proliferation in the G(1) phase of the cell cycle. Exp. Cell Res. 269, 171– 179.
- Yeh, H., Chang, H.M., Lu, W.W., Lee, Y.N., Ko, Y.S., Severs, N.J., Tsai, C.J., 2000. Age-related alteration of gap junction distribution and connexin expression in rat aortic endothelium. J. Histochem. Cytochem. 48, 1377– 1389.
- Yu, B.P., Chung, H.Y., 2001. Oxidative stress and vascular aging. Diabetes Res. Clin. Pract. 54 (Suppl. 2), S73–S80.
- Zwick, E., Hackel, P., Prenzel, N., Ullrich, A., 1999. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol. Sci. 20, 408–412.